Rallybio (RLYB)

Executive Summary

Rallybio is a public biotechnology company dedicated to developing transformative therapies for rare diseases, particularly those that have been historically underserved by science. The company's pipeline includes RLYB116, a novel therapeutic for hematologic and autoimmune diseases, which recently completed a Phase 1 trial (NCT06797375) with promising safety and pharmacokinetic data. Additionally, Rallybio was advancing an anti-integrin beta-3 monoclonal antibody for fetal and neonatal alloimmune thrombocytopenia (FNAIT), but the Phase 2 trial (NCT06435845) was terminated in 2025, likely due to enrollment challenges or strategic reprioritization. Despite this setback, the company continues to focus on high-unmet-need indications. With a market valuation of approximately $76 million and a lean pipeline, Rallybio represents a high-risk, high-reward opportunity, depending on successful advancement of RLYB116 into later-stage trials and potential partnerships.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 2 trial for RLYB11630% success
• Q4 2026Strategic partnership or licensing deal for FNAIT program20% success
• TBDData update from ongoing preclinical programs50% success